News | June 27, 2013

Sorin’s DREAM Study Shows Use of Pacemakers to Monitor Sleep Apnea

Sleep apnea monitoring in Sorin Reply 200 pacemakers validated against gold standard polysomnography

Sorin Group Reply Pacemakers Sleep Apnea Clinical Study

June 27, 2013 — Sorin Group announced the results of the DREAM clinical trial. In this study, the sleep apnea monitoring (SAM) algorithm of Sorin Reply 200 pacemakers was validated against polysomnography, the gold standard method used to measure the severity of sleep apnea (SA). Initial data show that Reply 200 with the new SAM algorithm provides reliable screening for the risk of severe SA[1].

In the DREAM study, 36 unselected patients with a pacemaker indication were implanted with Reply 200 pacemakers. Between one and two months after pacemaker implantation, these patients systematically underwent polysomnography examination to diagnose sleep disordered breathing. Automatic measurements obtained with Reply 200 pacemakers were compared to the polysomnography diagnosis for the same night. Sensitivity and specificity of the SAM algorithm to detect severe SA were 89 percent and 85 percent respectively.

Sleep apnea is highly prevalent[2] and vastly undiagnosed[3] in patients with pacemakers. It increases the risk of cardiovascular co-morbidities and mortality and complicates the management of common cardiovascular co-morbidities such as atrial fibrillation (AF) and heart failure (HF).[4,5]

The DREAM patient population exhibited an overall prevalence of moderate to severe SA of 75 percent, and an overall prevalence of severe SA of 50 percent. The majority of these patients did not have sleep apnea symptoms at the time of pacemaker implantation.

According to the principal study investigator, Pascal Defaye, M.D., at University Hospital, Grenoble, France, there is an increasing awareness of this often silent condition among cardiologists. Defaye added: “The consequences of sleep apnea can be severe. However, in a majority of patients, the disease can be treated effectively if properly diagnosed. The new SAM algorithm in the Reply 200 pacemaker is promising for screening patients at risk of severe sleep apnea. Having a reliable and validated indicator for pacemaker patients will improve the quality of healthcare they receive.”

"As the world's smallest pacemaker with unmatched longevity and offering our proprietary SafeR algorithm to minimize ventricular pacing, the REPLY family of pacemakers is recognized as the industry's gold standard,” said Stefano Di Lullo, Sorin Group, president of the CRM Business. “We are very pleased to add innovative sleep apnea screening to our pacemaker offering with the launch of Reply 200. This will further entrench our innovation leadership in the pacemaker market."

DREAM results were presented during the EHRA Europace Congress, June 23 - 26, held in Athens, Greece.

For more information: www.sorin.com

References:

1 Refer to user’s manual furnished with the device for complete instructions for use. SBD screening/SAM is NOT a formal indication, instead, it is used as a reference point for further diagnostics work by additional specialists. REPLY 200 pacemakers are not available for sale or distribution in the USA.

2 Garrigues S, Pépin JL, Defaye P, et al. High Prevalence of Sleep Apnea Syndrome in Patients With Long-Term Pacing: The European Multicenter Polysomnographic Study , Circulation. 2007;115:1703-1709.

3 Lee W, Nagubadi S, Kryger MH, et al. Epidemiology of Obstructive Sleep Apnea: a Population-based.Perspective, Expert Rev Respir Med. 2008 June 1; 2(3): 349–364.

4 Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study, Circulation 2010 July 27; 122(4):352-360.

5 Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006 Apr, 173:910-916.

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init